Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/12/2025

Erythema Multiforme Diagnosis and Management

Characterization and Clinical Features

  • Erythema multiforme is characterized by specific cutaneous manifestations without systemic fluid accumulation, and does not present with anasarca (generalized massive edema), as stated by the British Journal of Dermatology guidelines 1
  • Prodromal symptoms may include fever, malaise, and upper respiratory symptoms, and cutaneous pain can be a prominent early feature, as reported in the British Journal of Dermatology 1
  • Localized edema in affected areas, particularly in the hands and feet, can occur, but this is distinctly different from anasarca, as stated in the American Family Physician guidelines 2

Differential Diagnosis

  • Kawasaki Disease and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis should be considered in the differential diagnosis, as they present with distinct features such as localized edema and widespread epidermal detachment, respectively, according to the American Family Physician, Circulation, and British Journal of Dermatology guidelines 1, 2, 3
  • Early erythema migrans (Lyme disease) typically becomes larger than 5 cm, and a small erythemic raised lesion should be monitored for expansion, considering Lyme disease evaluation if the lesion expands, as recommended by the Clinical Infectious Diseases guideline and the American Academy of Dermatology 4

Management and Treatment

  • The management of EM requires identification and treatment of the underlying cause, such as antiviral therapy for HSV-associated EM or discontinuation of offending medication, as supported by the British Journal of Dermatology 5
  • Skin biopsy may be necessary in atypical presentations, and topical steroid use should be limited to 2-4 weeks to prevent skin atrophy, especially on thin skin areas, as suggested by the Clinical Infectious Diseases guidelines and dermatology guidelines 6
  • Antifungal therapy, either topical or systemic, is required for tinea corporis, and antifungal cream (clotrimazole 1%) in addition to hydrocortisone may be considered if the lesion is scaling or has vesicles/pustules, as recommended by the Infectious Diseases Society of America and the Annals of Oncology guideline 6, 7
  • If the lesion is associated with systemic symptoms, obtaining a bacterial culture and considering systemic antibiotics if infection is suspected is recommended, as advised by the Annals of Oncology guideline 7
  • High-potency steroids should be avoided on the face, groin, or axillary regions due to increased risk of skin atrophy, as recommended by dermatology guidelines